Addition of pulse corticosteroids to oral prednisone in moderately active ulcerative colitis: a randomized, multicentre, open-label study by GETECCU
- 19 November 2025
- journal article
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 19 (11)
Abstract
Background: Oral corticosteroids remain the treatment of choice for moderately active ulcerative colitis (UC), achieving clinical remission in 30%-60% of patients. Objective: To compare the rates of steroid-free clinical-endoscopic remission at weeks 8 and 54 in patients treated with 3 methyl-prednisolone pulses before oral corticosteroids in moderately active UC versus those only receiving oral corticosteroids. Design: Prospective, open, multicentre, randomized, controlled trial. Patients with left/extensive, moderately active UC, naive to immunosuppressants and biological agents, were randomized to receive conventional treatment (CT) with oral prednisone 60 mg/day or the same regimen preceded by an additional daily pulse (AP) of 500 mg of methyl-prednisolone for 3 days. All patients who responded started oral mesalazine and were followed up until month 12 or clinical relapse. Results: Seventy-five patients were randomized: 39 were allocated to the CT arm and 36 to the AP arm. Overall, 21 patients achieved clinical-endoscopic remission (28%; 95% confidence interval [CI]: 23%-33%) at both weeks 8 and 54 without needing rescue treatments, being not significantly different between both study groups (23% [95%CI: 14%-32%] CT vs. 33% [95%CI: 21%-45%] AP; P = 0.323). Patients in the AP group had higher rates of clinical response at day 3 and remission at day 7. No significant differences in adverse events were observed. Due to early termination, the study was underpowered, and findings should be interpreted as exploratory. Conclusions: The addition of 3 pulses of high-dose corticosteroids to a conventional regimen of oral prednisone does not improve medium and long-term clinical outcomes in moderately active UC. Trial registration codes: EudraCT number 2016-001170-15; ClinicalTrials.gov identifier NCT02921555.Keywords
Funding Information
- Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa
- Tillots Pharma
- Gobierno Vasco-Eusko Jaurlaritza (2020111061)
This publication has 18 references indexed in Scilit:
- Comparative analysis between the safety and efficacy of oral corticosteroids versus corticosteroids pulse therapies in IgA nephropathyRenal Failure, 2023
- ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical TreatmentJournal of Crohn's and Colitis, 2021
- Guía GETECCU 2020 para el tratamiento de la colitis ulcerosa. Elaborada con metodología GRADEGastroenterología y Hepatología, 2020
- ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complicationsJournal of Crohn's and Colitis, 2018
- Mucosal Healing Predicts Late Outcomes After the First Course of Corticosteroids for Newly Diagnosed Ulcerative ColitisClinical Gastroenterology and Hepatology, 2011
- Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics supportJournal of Biomedical Informatics, 2009
- Corticosteroids for the long-term treatment in multiple sclerosisCochrane Database of Systematic Reviews, 2008
- Outpatient Treatment of Moderately Severe Active Ulcerative Colitis with Pulsed Steroid Therapy and Conventional Steroid TherapyDigestive Diseases and Sciences, 2003
- A Prospective, Open-Label Trial Assessing Dexamethasone Pulse Therapy in Moderate to Severe Ulcerative ColitisJournal of Clinical Gastroenterology, 2002
- Coated Oral 5-Aminosalicylic Acid Therapy for Mildly to Moderately Active Ulcerative ColitisNew England Journal of Medicine, 1987